semaglutide weight loss liver transplant recipients Resmetirom and in metabolic dysfunction-associated steatohepatitis (MASH): a comparative perspective Obesity Is Increasing in Liver

Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, place-bo-controlled, phase 3 trial

The prion model for progression and diversity of neurodegenerative diseases

The most common side effects are injection site pain, redness, and transient warmth at the injection area

Ibuprofen-induced hepatitis can lead to fatality

In this context, using a previously reported -helical peptide as a template sequence (Behera et al., 2022), this study discusses the rational computational design and in silico evaluation of an -helical peptide (SR18: 18 aa) as a potent agonist of GLP-1R, with native GLP-1 and Semaglutide serving as references